Menu

Flu Vaccine-Narcolepsy Link Explained?

A new study sheds light on why those who received GlaxoSmithKline’s flu vaccine were at an increased risk of developing the sleep disorder.

Dec 20, 2013
Jef Akst

WIKIMEDIA, PEDRO SIMOESEditor’s note (August 1, 2014): This paper was retracted after the authors failed to reproduce the results.

People suffering from narcolepsy may be victims of their own immune system, according to a study published this week (December 18) in Science Translational Medicine. Specifically, researchers have found evidence to suggest that the sleep disorder might result from an immune reaction against the wakefulness-regulating hormone hypocretin—possibly one triggered GlaxoSmithKline’s Pandemrix flu vaccine that has been linked to an increased risk of developing narcolepsy, or even a case of the flu itself.

The work reveals “the fingerprints of an immune attack,” neuroimmunologist Lawrence Steinman of Stanford University in Palo Alto, California, who was not involved in the research, told ScienceNOW.

The results are “exactly what we’ve been waiting for,” added vaccine expert Hanna Nohynek of the National Institute for Health and Welfare in Helsinki, who helped identify the link between Pandemrix and narcolepsy.

In 2009, narcolepsy researcher Emmanuel Mignot of Stanford University and colleagues, funded in part by a GSK grant, discovered a curious link between the sleep disorder and immunity: nearly all narcolepsy patients have a particular type of human leukocyte antigen (HLA), molecules that present antigens to T cells to help the immune system distinguish self from non-self. Working in an immune cell line with the narcolepsy-associated HLA, Mignot and his colleagues tested the effects of hypocretin on T cells from either from one of four narcolepsy patients or from their identical twins that didn’t suffer from the disorder. For each set of twins, the researchers found that the T cells from the affected individual reacted to pieces of hypocretin that were displayed by the HLAs; T cells from the unaffected twin did not react.

The researchers also tested the T cells of 10 Irish children who had developed the sleep disorder following the administration of the Pandemrix vaccine, along with those from healthy siblings who were also vaccinated and carried the same HLA type. Once again, only the T cells taken from the narcolepsy patients reacted to the hypocretin epitopes.

Mignot’s team also tested the effects of the H1N1 virus hemagglutinin protein, which resembles hypocretin epitopes, and found that fragments of the viral protein also elicited an immune reaction. The findings suggest that narcolepsy could result from the immune system reacting to native molecules as a result of their similar structure to pathogenic proteins.

“[This] is the first mechanistic explanation of the disease,” vaccine expert Steven Black of Cincinnati Children’s Hospital Medical Center in Ohio told ScienceNOW. Of course, he added, “there’s plenty of work to do” to fully understand what leads to the onset of narcolepsy.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.